News Related to PD-1/VEGF Bispecific Antibody

Related coverage linked through entity extraction aliases.

Akeso Reports Survival Benefit in Phase III Lung Cancer Trial, Enrolls First Patient in Breast Cancer Study

Jun 15, 2026

Akeso reported overall survival benefit for ivonescimab plus chemotherapy in Phase III lung cancer study. The company enrolled first patient in Phase Ib/II trial of next-generation HER3 ADC AK138D1 for advanced breast cancer. Akeso also received China approval to start Phase II trials for AK139 bispecific antibody.

China biotech outlicensing surges as AbbVie strikes $745m Haisco pain deal

Apr 13, 2026

China’s cross-border biotech outlicensing hit US$60 billion in the first quarter of 2026. AbbVie’s up to $745 million Haisco pain deal highlights multinationals’ rising interest in Chinese drug assets.